Neurocrine Nears $2.5B Deal to Acquire Soleno Therapeutics
ArchivedVerified|4 articles|3 sources|1 blocks
Detected: Updated: Analyzed:
Reported Facts
Observable data points shared across all narratives
- •Neurocrine Biosciences is negotiating to buy Soleno Therapeutics for more than $2.5 billion.
- •Soleno Therapeutics develops treatments for obesity-related disorders.
- •The deal is reported by the Financial Times on April 6, 2026.
- •Soleno Therapeutics' stock price rose following the acquisition news.
- •Neurocrine aims to accelerate its obesity drug development through this acquisition.
What Could Happen If...
- ▸If Neurocrine completes the acquisition of Soleno Therapeutics Neurocrine could strengthen its position in the obesity treatment market and potentially increase its research and development output.
Market Exposure
StocksSoleno TherapeuticsUpward Pressure
Acquisition talks by Neurocrine increase demand for Soleno Therapeutics shares, pushing the price higher.
This is not investment advice. Market exposure is based on conditional event analysis.
Key Actors
Organizations
Source Coverage
FINANCE
4 articles
More coverage on this story
- More on Neurocrine Biosciences
- More on Soleno Therapeutics
Signals
Single-block coverage
Related Events
▸Sun Pharma Expands Global Reach with $11.75B Organon AcquisitionArchived▸Senseonics targets $58M–$62M revenue with sales integrationArchived▸Eli Lilly signs $2.75B deal with Insilico for AI drug developmentArchived▸Gilead nears $2bn buyout of biotech Ouro MedicinesArchived▸Coherus Targets $175M Annual LOQTORZI Sales by 2028
Primary Sources (4)
FINANCEMarketWatch - Top StoriesNeurocrine wants to develop new obesity drugs. It’s making an acquisition to accelerate that move.FINANCESeeking Alpha - Market NewsSoleno Therapeutics rallies on report of $2.5B Neurocrine buyout talksFINANCESeeking Alpha - Market NewsNeurocrine nears $2.5B-plus deal to buy Soleno Therapeutics - FTFINANCE